Maravai LifeSciences Holdings, Inc. filings document the formal disclosures of a Nasdaq-listed life sciences operating company with Class A common stock. Form 8-K reports furnish quarterly and annual financial results, including revenue, net loss, adjusted EBITDA and business updates for the TriLink nucleic acid synthesis and Cygnus biologics safety testing operations.
The company’s proxy materials describe annual meeting matters, director elections, independent auditor ratification, executive compensation votes and board governance. Other current reports record leadership succession, board-size and committee changes, equity-award treatment, and restructuring actions classified as exit or disposal activities, including related cost disclosures and risk language.
MARAVAI LIFESCIENCES HOLDINGS, INC. director and Chief Executive Officer Bernd Brust reported a transaction involving 29,250 shares of Class A Common Stock on 2026-08-10. These shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock unit awards, at a reference value of $6.23 per share. Following this tax-withholding disposition, Brust directly holds 1,590,499 Class A shares and has an additional 466,771 Class A shares held indirectly through The Bernd Brust Management Trust.
Maravai LifeSciences reported improved results for the quarter and six months ended June 30, 2026. Revenue reached $51,442 thousand in Q2 and $117,279 thousand year‑to‑date, led by TriLink growth. Gross margin rose to 40.1% in Q2 and 46.3% for the first half.
The company still recorded a net loss attributable to Maravai of $12,416 thousand in Q2 and $16,149 thousand year‑to‑date, but Adjusted EBITDA turned positive at $8,674 thousand for Q2 and $29,001 thousand for the first half. Operating cash flow improved to an inflow of $12,657 thousand, while cash and restricted cash declined to $70,581 thousand after refinancing into a new $150.0 million term loan maturing in 2032. Management does not expect further high‑volume CleanCap® revenue from commercial COVID‑19 vaccine programs in 2026.
Maravai LifeSciences Holdings, Inc. reported second quarter 2026 revenue of $51.4 million, up 8.5% year over year, with TriLink growing 11.5% and Cygnus up 2.8%. Net loss narrowed to $(21.6) million from $(69.8) million, and Adjusted EBITDA improved to $8.7 million from $(10.4) million.
For the six months ended June 30, 2026, total revenue increased 24.4%, driven by TriLink’s 37.3% growth, including $14.3 million of high‑volume CleanCap orders, while Cygnus grew 2.1%. Six‑month net loss was $(28.0) million versus $(122.7) million, and Adjusted EBITDA rose to $29.0 million from $(21.0) million.
The company reiterated full‑year 2026 revenue guidance of $205.0–$215.0 million and raised Adjusted EBITDA guidance to $33.0–$35.0 million from $30.0–$32.0 million. Management highlighted a new GMP enzyme manufacturing facility and continued adoption of the ModTail™ product line, now with more than 125 active customers.
Maravai Lifesciences Holdings, Inc. reported that Chief Financial Officer Rajesh Asarpota had 5,465 shares of Class A Common Stock withheld on July 30, 2026, at $6.59 per share to satisfy tax withholding obligations related to the vesting of restricted stock unit awards. After this tax-withholding disposition, he directly holds 428,951 shares. The transaction was not reported as made pursuant to a Rule 10b5-1 trading plan.
MARAVAI LIFESCIENCES HOLDINGS, INC. Chief Executive Officer Bernd Brust reported routine equity compensation-related activity in Class A Common Stock. A total of 29,250 shares were withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards, a non-open-market, tax-related disposition. Following these transactions, Brust holds 1,619,749 Class A shares directly and 466,771 Class A shares indirectly through The Bernd Brust Management Trust.
Maravai Lifesciences Holdings Chief Financial Officer Rajesh Asarpota reported a routine share disposition related to equity compensation. On the vesting of restricted stock unit awards, 65,584 shares of Class A Common Stock were withheld at $6.39 per share to satisfy tax withholding obligations, rather than being sold on the open market. After this tax withholding event, Asarpota directly holds 434,416 shares of Maravai Lifesciences Class A Common Stock.
Maravai LifeSciences Holdings, Inc. Schedule 13G shows that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported acquiring beneficial ownership of more than 5% of the Class A common stock on 06/23/2026, and state they ceased to be beneficial owners of more than 5% by the date of this filing. The cover data lists 6,900,258 shares associated with shared voting and dispositive power, representing 4.7% of the class as reported on the cover pages. A Joint Filing Agreement dated 06/26/2026 is attached and the filing is signed by Gil Raviv and Israel A. Englander.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander filed a Schedule 13G reporting shared beneficial ownership of 7,323,520 shares (4.96%) of Maravai LifeSciences Holdings, Inc. Class A common stock (CUSIP 56600D107) with a June 16, 2026 ownership date.
The filing states the reported shares reflect shared voting and shared dispositive power of 7,323,520 and notes that, after acquiring beneficial ownership of more than 5% on June 16, 2026, the reporting persons ceased to be beneficial owners of more than 5% by the date of this filing. The filing is accompanied by a Joint Filing Agreement dated June 22, 2026.
MARAVAI LIFESCIENCES HOLDINGS, INC. director and Chief Executive Officer Bernd Brust reported routine share movements related to equity compensation. On June 8, 2026, 351,001 shares of Class A Common Stock were withheld at $5.02 per share to satisfy tax obligations from restricted stock unit vesting, which is not an open-market sale.
After these transactions, Brust directly owns 1,648,999 shares of Class A Common Stock and indirectly holds 466,771 shares through The Bernd Brust Management Trust, indicating a substantial remaining equity position in the company.
MARAVAI LIFESCIENCES HOLDINGS, INC. General Counsel Kurt Oreshack reported open-market sales of Class A Common Stock. He sold 25,000 shares on June 9, 2026 at $5.06 per share and 25,000 shares on June 10, 2026 at $5.10 per share. These transactions were effected under a pre-arranged Rule 10b5-1 trading plan. Following the sales, he directly holds 335,767 shares of Maravai Lifesciences stock.